<DOC>
	<DOCNO>NCT02444286</DOCNO>
	<brief_summary>To evaluate safety efficiency MitraClip system treatment patient clinically significant mitral regurgitation New York Heart Association ( NYHA ) Functional Class II IV chronic heart failure .</brief_summary>
	<brief_title>The RESHAPE-HF1-FU Study</brief_title>
	<detailed_description>The purpose RESHAPE-HF1-FU Study follow safety effectiveness MitraClip System treatment clinically significant Functional Mitral Regurgitation ( FMR ) patient New York Heart Association ( NYHA ) Functional Class III IV chronic heart failure , former participant RESHAPE-HF Trial ( Abbott Vascular ) .</detailed_description>
	<mesh_term>Mitral Valve Insufficiency</mesh_term>
	<criteria>Former participant RESHAPEHF Trial ( Abbott Vascular ) Subject agree return require followup visit The subject inform nature study agree study 's provision provide write informed consent approve respective clinical site 's Ethics Committee Withdrawal Informed Consent Subject belong vulnerable population</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>